...
首页> 外文期刊>British Journal of Cancer >Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: Report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group
【24h】

Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: Report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group

机译:英国青少年和年轻人进入国家癌症研究网络临床试验的比率:国家癌症研究所(NCRI)青少年和成人临床研究发展小组的报告

获取原文
           

摘要

Poor inclusion rates into clinical trials for teenagers and young adults (TYA; aged 13–24 years) have been assumed but not systematically investigated in England. We analysed accrual rates (AR) from 1 April 2005 up to 31 March 2007 to National Cancer Research Network (NCRN) Phase III trials for the commonest tumour types occurring in TYA and children: leukaemia, lymphoma, brain and central nervous system, bone sarcomas and male germ cell tumours. AR for 2005–2007 were 43.2% for patients aged 10–14 years, 25.2% for patients aged 15–19 years, and 13.1% for patients aged 20–24 years in the tumour types analysed. Compared with accrual from 1 April 2005 to 31 March 2006, AR between 1 April 2006 and 31 March 2007 increased for those aged 10–14 and 15–19 years, but fell for those aged 20–24 years. AR varied considerably among cancer types. Despite four trials being available, patients over 16 years with central nervous system tumours were not recruited. Rates of participation in clinical trials in England from 2005 to 2007 were much lower for TYA older than 15 years compared with children and younger teenagers. The variations in open trials, trial age eligibility criteria and extent of trial activation in treatment centres in part explain this observation. Other possible influences, such as difficulties associated with the consent of TYA require further evaluation. Closer dialogue between those involved in planning and running trials for children and for adults is necessary to improve trial availability and recruitment. Further research is required to identify trends in trial availability and accrual for those tumours constituting the remaining 26% of TYA cancers.
机译:假定青少年在青少年(TYA; 13-24岁)的临床试验中纳入率较低,但在英格兰尚未进行系统的调查。我们分析了2005年4月1日至2007年3月31日在国家癌症研究网络(NCRN)进行的TYA和儿童中最常见的肿瘤类型:白血病,淋巴瘤,脑和中枢神经系统,骨肉瘤的III期试验的应计率和男性生殖细胞肿瘤。在分析的肿瘤类型中,2005年至2007年的AR在10-14岁的患者中为43.2%,在15-19岁的患者中为25.2%,在20-24岁的患者中为13.1%。与2005年4月1日至2006年3月31日的应计额相比,2006年4月1日至2007年3月31日的应收税率在10-14岁和15-19岁的人群中有所增加,但在20-24岁的人群中有所下降。在癌症类型之间,AR差异很大。尽管有四项试验可用,但未招募16岁以上中枢神经系统肿瘤患者。与儿童和青少年相比,年龄在15岁以上的TYA在2005年至2007年在英格兰的临床试验参与率要低得多。开放式试验,试验年龄资格标准和治疗中心试验激活程度的差异部分解释了这一观察结果。其他可能的影响,例如与TYA同意相关的困难,需要进一步评估。为了提高可用性和招募人数,有必要在为儿童和成人进行计划和运行试验的人员之间进行更密切的对话。需要进一步的研究来确定构成剩下的26%TYA癌症的那些肿瘤的试验可用性和应计趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号